Methods and compositions for interfering with extraction or conversion of a drug susceptible to abuse

ABSTRACT

Effective methods and compositions to deter abuse of pharmaceutical products (e.g., orally administered pharmaceutical products) including but not limited to immediate release, sustained or extended release and delayed release formulations for drugs subject to abuse.

CROSS-REFERENCE TO RELATED APPLICATIONS

The present application claims priority benefit from U.S. ProvisionalPatent Application No. 62/009,600, filed Jun. 9, 2014, the entiresubject matter of which is hereby incorporated herein by reference inits entirety.

BACKGROUND

Drug abusers and/or addicts typically may take a solid dosage formintended for oral administration containing one or more active drugs andcrush, shear, grind, chew, dissolve and/or heat, extract or otherwisetamper with or damage the dosage form so that a significant portion oreven the entire amount of the active drug becomes available foradministration.

An abuser may convert a precursor compound found in a dosage form byillicit chemical processes. Examples of such methods include the NaziMethod, the Red Phosphorus Method, and the Shake and Bake Method.

The Shake and Bake Method is a method in which methamphetamine may besynthesized in a single container, also known as a “one-pot” system.Readily accessible non-polar solvents such as camp stove fuel (e.g.COLEMAN® Fuel) are often used in the Shake and Bake method.

There is a growing need for novel and effective methods and compositionsto deter abuse of pharmaceutical products (e.g., orally administeredpharmaceutical products) including but not limited to immediate release,sustained or extended release and delayed release formulations for drugssubject to abuse.

SUMMARY OF THE INVENTION

In certain embodiments therapeutic composition includes apharmacologically effective amount of a drug susceptible to direct orindirect abuse, a triglyceride, hydroxypropylcellulose, polyethyleneoxide, and a disintegrant selected from the group consisting ofcrospovidone, sodium starch glycolate and croscarmellose sodium. In someembodiments the drug susceptible to direct or indirect abuse ispseudoephedrine. In some embodiments, the therapeutic composition is animmediate release formulation.

In some embodiments, the drug susceptible to abuse comprises a watersoluble drug or salt thereof. In some embodiments the drug susceptibleto abuse comprises a precursor compound (e.g. pseudoephedrine) that canbe chemically converted to a different drug (e.g. methamphetamine) thatcan then be directly abused. In some embodiments the pharmacologicallyeffective amount of a drug susceptible to direct or indirect abuse is apharmacologically effective amount of pseudoephedrine or a salt thereof.

In some embodiments, the drug susceptible to abuse comprises one or moreof alfentanil, amphetamines, buprenorphine, butorphanol, carfentanil,codeine, dezocine, diacetylmorphine, dihydrocodeine, dihydromorphine,diphenoxylate, diprenorphine, etorphine, fentanyl, hydrocodone,hydromorphone, β-hydroxy-3-methylfentanyl, levo-α-acetylmethadol,levorphanol, lofentanil, meperidine, methadone, methylphenidate,morphine, nalbuphine, nalmefene, o-methylnaltrexone, naloxone,naltrexone, oxycodone, oxymorphone, pentazocine, pethidine,propoxyphene, remifentanil, sufentanil, tilidine, tramodol, and saltsthereof.

In some embodiments, the hydroxypropylcellulose has a viscosity of about1,500 mPa to about 3,000 mPa at a concentration of 1% in water. in someembodiments, the hydroxypropylcellulose has a molecular weight of about1,150,000.

In some embodiments, the polyethylene oxide is present in an amount ofabout 3 wt % to about 7 wt %. In some embodiments, the polyethyleneoxide is present in an amount of about 5 to about 10 wt %. In someembodiments, the crospovidone is present in an amount of about 15 wt %to about 25 wt %; or about 18 wt % to about 22 wt %.

In some embodiments, the triglyceride has a melting point of about 50°C. to about 80° C. In some embodiments the triglyceride is tristearin.

In certain embodiments, a composition suitable for reducing the chemicalconversion of precursor compounds included in the composition to a drugsusceptible to abuse includes a precursor compound that can be used in achemical synthesis of a drug that is susceptible to abuse; atriglyceride, hydroxypropylcellulose; polyethylene oxide; and adisintegrant selected from the group consisting of crospovidone, sodiumstarch glycolate and croscarmellose sodium. In some embodiments, theprecursor compound includes pseudoephedrine or salts thereof, (e.g.pseudoephedrine HCl). In some embodiments, the composition is animmediate release composition. In some embodiments the unit does form isa direct compressed unit dose form.

In certain embodiments a method of making a composition suitable forreducing the chemical conversion of precursor compound included in thecomposition to a drug susceptible to abuse includes providingingredients comprising: a precursor compound that can be used in achemical synthesis of a drug that is susceptible to abuse; atriglyceride, hydroxypropylcellulose; polyethylene oxide, and adisintegrant selected from the group consisting of crospovidone, sodiumstarch glycolate, and croscarmellose sodium; and directly compressingthe ingredients into a unit dose form.

DETAILED DESCRIPTION OF THE INVENTION

The present invention restricts, reduces or diminishes thecrystallization and/or extraction of a drug that has been converted byillicit means from a precursor drug. In some embodiments the presentinvention provides a pharmaceutical composition that includes atherapeutically active pharmaceutical with one or more triglyceridesthat are soluble in a non-polar solvent.

Without being bound by a particular mode of action, in some embodiments,therapeutic compositions of the present invention can interfere with thecrystallization of a drug susceptible to abuse by forming a complex insolution with the converted drug. The triglyceride present incompositions of some embodiments of the present invention is soluble innon-polar organic solvents. Examples of such drugs susceptible to abuseare methamphetamine or methionine, which have been converted from aprecursor drug such as pseudoephedrine, obtained from a pseudoephedrinedosage form. Examples of such non-polar solvents include, but are notlimited to, cyclohexane, nonane, octane, heptane, pentane, and mixturesthereof, including, but not limited to COLEMAN® Fuel (also referred toas naptha or white gas).

A. Constituents of an Abuse Deterrent Formulation

1. Drugs Suitable for Use with the Present Invention

In some embodiments, the drug for use in the present invention caninclude precursor compounds which can be converted to other abusabledrugs and include, but are not limited to, sympathomimetic amines,amphetamine-like compounds, amphetamine and methamphetamine precursorsincluding ephedrine, norpseudoephedrine, pseudoephedrine,pseudoephedrine HCl, pseudoephedrine sulfate, phenylpropanolamine,methylphenidate, and salts, derivatives, analogs, homologues, polymorphsthereof, and mixtures of any of the foregoing. In some embodiments, thedrug for use in the present invention can include pseudoephedrine HCl.

Any drug, therapeutically acceptable drug salt, drug derivative, druganalog, drug homologue, or polymorph can be used in the presentinvention. In one embodiment, the drug is an orally administered drug.In certain embodiments, drugs susceptible to abuse are used. Drugscommonly susceptible to abuse include psychoactive drugs and analgesics,including but not limited to opioids, opiates, stimulants,tranquilizers, narcotics and drugs that can cause psychological and/orphysical dependence. In some embodiments, the present invention caninclude any of the resolved isomers of the drugs described herein,and/or salts thereof.

In some embodiments, a drug for use in the present invention which canbe susceptible to abuse can be one or more of the following: alfentanil,amphetamines, buprenorphine, butorphanol, carfentanil, codeine,dezocine, diacetylmorphine, dihydrocodeine, dihydromorphine,diphenoxylate, diprenorphine, etorphine, fentanyl, hydrocodone,hydromorphone, β-hydroxy-3-methylfentanyl, levo-α-acetylmethadol,levorphanol, lofentanil, meperidine, methadone, methylphenidate,morphine, nalbuphine, nalmefene, o-methylnaltrexone, naloxone,naltrexone, oxycodone, oxymorphone, pentazocine, pethidine,propoxyphene, remifentanil, sufentanil, tilidine and tramodol, salts,derivatives, analogs, homologues, polymorphs thereof, and mixtures ofany of the foregoing.

In some embodiments, a drug for use with the present invention which canbe susceptible to abuse includes one or more of the following:N-{1-[2-(4-ethyl-5-oxo-2-tetrazolin-1-yl)-ethyl]-4-methoxymethyl-4-piperidyl}propionanilide(alfentanil), 5,5-diallyl barbituric acid (allobarbital), allylprodine,alpha-prodine,8-chloro-1-methyl-6-phenyl-4H-[1,2,4]triazolo[4,3-a][1,4]-benzodiazepine(alprazolam), 2-diethylaminopropiophenone (amfepramone), (±)-α-methylphenethylamine (amphetamine), 2-(α-methylphenethyl-amino)-2-phenylacetonitrile (amphetaminil), 5-ethyl-5-isopentyl barbituric acid(amobarbital), anileridine, apocodeine, 5,5-diethyl barbituric acid(barbital), benzylmorphine, bezitramide,7-bromo-5-(2-pyridyl)-1H-1,4-benzodiazepin-2(3H)-one (bromazepam),2-bromo-4-(2-chlorophenyl)-9-methyl-6H-thieno[3,2-f][1,2,4]-triazolo[4,3-a][1,4]diazepine(brotizolam),17-cyclopropylmethyl-4,5α-epoxy-7α[(S)-1-hydroxy-1,2,2-trimet-hylpropyl]-6-methoxy-6,14-endo-ethanomorphinan-3-ol(buprenorphine), 5-butyl-5-ethyl barbituric acid (butobarbital),butorphanol,(7-chloro-1,3-dihydro-1-methyl-2-oxo-5-phenyl-2H-1,4-benzodiazepin-3-yl)-dimethylcarbarnate (camazepam), (1S,2S)-2-amino-1-phenyl-1-propanol(cathine/D-norpseudoephedrine),7-chloro-N-methyl-5-phenyl-3H-1,4-benzodiazepin-2-ylamine-4 oxide(chlordiazepoxide),7-chloro-1-methyl-5-phenyl-1H-1,5-benzodiazepine-2,4(3H,5H)-dione(clobazam), 5-(2-chlorophenyl)-7-nitro-1H-1,4-benzodiazepin-2(3H)-one(clonazepam), clonitazene,7-chloro-2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepine-3-carboxylicacid (clorazepate),5-(2-chlorophenyl)-7-ethyl-1-methyl-1H-thieno[2,3-e][1,4]-diazepin-2(3H)-one(clotiazepam),10-chloro-11b-(2-chlorophenyl)-2,3,7,11b-tetrahydrooxazolo[3,2-d][1,4]benzodiazepin-6(5H)-one(cloxazolam), (−)-methyl[3β-benzoyloxy-2β(1αH,5αH)-tropane carboxylate(cocaine), 4,5α-epoxy-3-methoxy-17-methyl-7-morphinen-6α-ol (codeine),5-(1-cyclohexenyl)-5-ethyl barbituric acid (cyclobarbital), cyclorphan,cyprenorphine,7-chloro-5-(2-chlorophenyl)-1H-1,4-benzodiazepin-2(3H)-one(delorazepam), desomorphine, dextromoramide,(+)-(1-benzyl-3-dimethylamino-2-methyl-1-phenylpropyl)propionate(dextropropoxyphene), dezocine, diampromide, diamorphone,7-chloro-1-methyl-5-phenyl-1H-1,4-benzodiazepin-2(3H)-one (diazepam),4,5α-epoxy-3-methoxy-17-methyl-6α-morphinanol (dihydrocodeine),4,5α-epoxy-17-methyl-3,6α-morphinandiol (dihydromorphine), dimenoxadol,dimephetamol [sic-Tr.Ed], dimethyl thiambutene, dioxaphetyl butyrate,dipipanone,(6aR,10aR)-6,6,9-trimethyl-3-pentyl-6a,7,8,10a-tetrahydro-6H-benzo[c]chro-men-1-ol(dronabinol), eptazocine,8-chloro-6-phenyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine(estazolam), ethoheptazine, ethyl methyl thiambutene,ethyl-[7-chloro-5-(2-fluorophenyl)-2,3-dihydro-2-oxo-1H-1,4-benzodiazepin-3-carboxylate](ethylloflazepate), 4,5α-epoxy-3-ethoxy-17-methyl-7-morphinen-6α-ol(ethylmorphine), etonitrazene,4,5α-epoxy-7α-(1-hydroxy-1-methylbutyl)-6-methoxy-17-methyl-6-,14-endo-etheno-morphinan-3-ol(etorphine), N-ethyl-3-phenyl-8,9,10-trinorbornan-2-ylamine(fencamfamine), 7-[2-(α-methylphenethylamino)-ethyl]theophylline(fenethylline), 3-(α-methylphenethylamino)propionitrile (fenproporex),N-(1-phenethyl-4-piperidyppropionanilide (fentanyl),7-chloro-5-(2-fluorophenyl)-1-methyl-1H-1,4-benzodiazepin-2(3H)-one(fludiazepam),5-(2-fluorophenyl)-1-methyl-7-nitro-1H-1,4-benzodiazepin-2-(3H)-one(flunitrazepam),7-chloro-1-(2-diethylaminoethyl)-5-(2-fluorophenyl)-1H-1,4-benzodiazepin-2(3H)-one(flurazepam),7-chloro-5-phenyl-1-(2,2,2-trifluoroethyl)-1H-1,4-benzodiazepin-2(3H)-one(halazepam),10-bromo-11b-(2-fluorophenyl)-2,3,7,11b-tetrahydro[1,3]oxazolo[3,2-d][1,4-]benzodiazepin-6(5H)-one(haloxazolam), heroin, 4,5α-epoxy-3-methoxy-17-methyl-6-morphinanone(hydrocodone), 4,5α-epoxy-3-hydroxy-17-methyl-6-morphinanone(hydromorphone), hydroxypethidine, isomethadone, hydroxymethylmorphinan,11-chloro-8,12b-dihydro-2,8-dimethyl-12b-phenyl-4H-[1,3]oxazino[3,2-d][1,-4]benzodiazepin-4,7(6H)-dione(ketazolam), 1-[4-(3-hydroxyphenyl)-1-methyl-4-piperidyl]-1-propanone(ketobemidone), (3S,6S)-6-dimethylamino-4,4-diphenylheptan-3-yl acetate(levacetylmethadol (LAAM)), (−)-6-dimethylamino-4,4-diphenyl-3-heptanone(levomethadone), (−)-17-methyl-3-morphinanol (levorphanol), levophenacylmorphan, lofentanil,6-(2-chlorophenyl)-2-(4-methyl-1-piperazinylmethylene)-8-nitro-2H-imidazo-[1,2a][1,4]benzodiazepin-1(4H)-one(loprazolam),7-chloro-5-(2-chlorophenyl)-3-hydroxy-1H-1,4-benzodiazepin-2(3H)-one(lorazepam),7-chloro-5-(2-chlorophenyl)-3-hydroxy-1-methyl-1H-1,4-benzodiazepin-2(3H)-one(lormetazepam),5-(4-chlorophenyl)-2,5-dihydro-3H-imidazo[2,1-a]isoindol-5-ol(mazindol), 7-chloro-2,3-dihydro-1-methyl-5-phenyl-1H-1,4-benzodiazepine(medazepam), N-(3 -chloropropyl)-α-methylphenetylamine (mefenorex),meperidine, 2-methyl-2-propyl trimethylene dicarbamate (meprobamate),meptazinol, metazocine, methylmorphine, N,α-dimethylphenethylamine(methamphetamine), (+)-6-dimethylamino-4,4-diphenyl-3-heptanone(methadone), 2-methyl-3-o-tolyl-4(3H)-quinazolinone (methaqualone),methyl-[2-phenyl-2-(2-piperidyl)acetate](methyl phenidate),5-ethyl-1-methyl-5-phenyl barbituric acid (methyl phenobarbital),3,3-diethyl-5-methyl-2,4-piperidinedione (methyprylon), metopon,8-chloro-6-(2-fluorophenyl)-1-methyl-4H-imidazo[1,5-a][1,4]benzodiazepine(midazolam), 2-(benzhydrylsulfinyl)acetamide (modafinil),4,5α-epoxy-17-methyl-7-morphinene-3,6α-diol (morphine), myrophine,(+)-trans-3-(1,1-dimethylheptyl)-7,8,10,10α-tetrahydro-1-hydroxy-6,6-dimethyl-6H-dibenzo[b,d]pyran-9(6αH)-one(nabilone), nalbuphen, nalorphine, narceine, nicomorphine,1-methyl-7-nitro-5-phenyl-1H-1,4-benzodiazepin-2(3H)-one (nimetazepam),7-nitro-5-phenyl-1H-1,4-benzodiazepin-2(3H)-one (nitrazepam),7-chloro-5-phenyl-1H-1,4-benzodiazepin-2-(3H)-one (nordazepam),norlevorphanol, 6-dimethylamino-4,4-diphenyl-3-hexanone (normethadone),normorphine, norpipanone, the coagulated juice of the plants belongingto the species Papaver somniferum (opium),7-chloro-3-hydroxy-5-phenyl-1H-1,4-benzodiazepin-2-(3H)-one (oxazepam),(cis-trans)-10-chloro-2,3,7,11b-tetrahydro-2-methyl-11b-phenyloxazolo[3,2-d][1,4]benzodiazepin-6-(5H)-one(oxazolam), 4,5α-epoxy-14-hydroxy-3-methoxy-17-methyl-6-morphinanone(oxycodone), oxymorphone, plants and plant parts of the plants belongingto the species Papaver somniferum (including the subspecies setigerum)(Papaver somniferum), papaveretum, 2-imino-5-phenyl-4-oxazolidinone(pernoline),1,2,3,4,5,6-hexahydro-6,11-dimethyl-3-(3-methyl-2-butenyl)-2,6-methano-3-benzazocin-8-ol(pentazocine), 5-ethyl-5-(1-methylbutyl)barbituric acid (pentobarbital),ethyl-(1-methyl-4-phenyl-4-piperidine-carboxylate) (pethidine),phenadoxone, phenomorphan, phenazocine, phenoperidine, piminodine,pholcodeine, 3-methyl-2-phenyl morpholine (phenmetrazine),5-ethyl-5-phenyl barbituric acid (phenobarbital), α,α-dimethylphenethylamine (phentermine),7-chloro-5-phenyl-1-(2-propinyl)-1H-1,4-benzodiazepin-2(3H)-one(pinazepam), α-(2-piperidyl)benzhydryl alcohol (pipradol),1′-(3-cyano-3,3-diphenylpropyl)[1,4′-biperidine]-4′-carboxamide(piritramide),7-chloro-1-(cyclopropylmethyl)-5-phenyl-1H-1,4-benzodiazepin-2(3H)-one(prazepam), profadol, proheptazine, promedol, properidine, propoxyphene,N-(1-methyl-2-piperidinoethyl)-N-(2-pyridyl)propionamide,methyl-{3-[4-methoxycarbonyl-4-(N-phenylpropaneamido)piperidino]propanoat-e}(remifentanil),5-sec.-butyl-5-ethyl barbituric acid (secbutabarbital),5-allyl-5-(1-methylbutyl)barbituric acid (secobarbital),N-{4-methoxymethyl-1-[2-(2-thienyl)ethyl]-4-piperidyl}propionanilide(sufentanil),7-chloro-2-hydroxy-methyl-5-phenyl-1H-1,4-benzodiazepin-2-(3H)-one(temazepam),7-chloro-5-(1-cyclohexenyl)-1-methyl-1H-1,4-benzodiazepin-2(3H)-one(tetrazepam),ethyl-(2-dimethylamino-1-phenyl-3-cyclohexane-1-carboxylate)(tilidine-(cis and trans)), tramadol,8-chloro-6-(2-chlorophenyl)-1-methyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzod-iazepine(triazolam), 5-(1-methylbutyl)-5-vinyl barbituric acid (vinylbital),(1R*,2R*)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol,(1R,2R,4S)-2-[dimethylamino)methyl-4-(p-fluorobenzyloxy)-1-(m-methoxyphenyl)cyclohexanol,each optionally in the form of corresponding stereoisomeric compounds aswell as corresponding derivatives, especially esters or ethers, and allbeing physiologically compatible compounds, especially salts andsolvates.

In some embodiments a drug may be present in a therapeutic compositionin a pharmacologically effective amount. In some embodiments, a drug maybe present in a therapeutic composition in an amount of about 1 wt % toabout 25 wt %; about 1 wt % to about 22 wt %; about 1 wt % to about 20wt %; about 1 wt % to about 18 wt %; about 1 wt % to about 16 wt %;about 1 wt % to about 14 wt %; about 1 wt % to about 12 wt %; about 2 wt% to about 10 wt %; about 2 wt % to about 8 wt %; about 3 wt % to about8 wt %; about 4 wt % to about 7 wt %; about 5 wt % to about 7 wt %, orabout 6 wt % to about 7 wt %. In some embodiments, a drug may be presentin a therapeutic composition in an amount of about 1 wt %; about 1.5 wt%; about 2 wt %; about 2.5 wt %; about 3 wt %; about 3.5 wt %; about 4wt %; about 4.5 wt %; about 5 wt %; about 5.5 wt %; about 6 wt %; about6.5 wt %; about 7 wt %; about 7.5 wt %; about 8 wt %; about 8.5 wt %;about 9 wt %; about 9.5 wt %; about 10 wt %; about 10.5 wt %; about 11wt %; about 11.5 wt %; about 12 wt %; about 12.5 wt %; about 13 wt %;about 13.5 wt %; about 14 wt %; about 14.5 wt %; about 15 wt % about15.5 wt %; about 16 wt %; about 16.5 wt %; about 17 wt %; about 17.5 wt%; about 18 wt %; about 18.5 wt %; about 19 wt %; about 19.5 wt %; about20 wt %; about 21 wt %; about 22 wt %; about 23 wt %; about 24 wt %; orabout 25 wt %. In some embodiments, a drug may be present in atherapeutic composition in an amount of about 612 wt %.

In some embodiments, a drug is present in a therapeutic composition inan amount of about 1 mg, about 2 mg, about 3 mg, about 4 mg, about 5 mg,about 6 mg, about 7 mg, about 8 mg, about 9 mg, about 10 mg, about 11mg, about 12, mg, about 13 mg, about 14 mg, about 15 mg, about 16 mg,about 17 mg, about 18 mg, about 19 mg, about 20 mg, about 2.1 mg, about22 mg, about 23 mg, about 24 mg, about 25 mg, about 26 mg, about 27 mg,about 28 mg, about 29 mg, about 30 mg, about 31 mg, about 32 mg, about33 mg, about 34 mg, about 35 mg, about 36 mg, about 37 mg, about 38 mg,about 39 mg, about 40 mg, about 41 mg, about 42 mg, about 43 mg, about44 mg, about 45 mg, about 46 mg, about 47 mg, about 48 mg, about 49 mg,about 50 mg, about 55 mg, about 60 mg, about 65 mg, about 70 mg, about75 mg, about 80 mg, about 85 mg, about 90 mg, about 95 mg, about 100 mg,about 125 mg, about 150 mg, about 175 mg, about 200 mg; about 225 mg,about 240 mg, or about 250 mg.

In some embodiments, a pharmaceutical composition of the presentinvention includes one or more opioids such as hydrocodone, morphine andoxycodone and/or salts thereof, as the therapeutically activeingredient. Typically when processed into a suitable dosage form, thedrug can be present in such dosage forms in an amount normallyprescribed, typically about 0.5 to about 25 percent on a dry weightbasis, based on the total weight of the formulation.

In some embodiments, a pharmaceutical composition of the presentinvention includes one or more analgesics that are not typicallysusceptible to abuse, such as acetominophen (also referred to asparacetamol, APAP, or N-acetyl-p-aminophenol), salts thereof, orformulations thereof (e.g. COMPAP™ L), in addition to a drug which issusceptible to abuse, described above. Typically when processed into asuitable dosage form, the analgesic can be present in such dosage formsin an amount normally prescribed, typically about 0.5 to about 50percent on a dry weight basis, based on the total weight of theformulation. In some embodiments the analgesic can be present in anamount of about 10 percent to about 40 percent, about 15 percent toabout 35 percent, or about 20 percent to about 25 percent. In someembodiments the analgesic can be present in an amount of about 5percent, about 10 percent, about 15 percent, about 20 percent, about 25percent, about 30 percent, about 35 percent, about 40 percent, about 45percent, or about 50 percent.

With respect to analgesics in unit dose form, such an amount can betypically from about 5, 25, 50, 75, 100, 125, 150, 175 or 200 mg. Moretypically, the analgesic that is not typically susceptible to abuse canbe present in an amount from 5 to 500 mg or even 5 to 200 mg. In someembodiments, a dosage form contains an appropriate amount of analgesicthat is not typically susceptible to abuse to provide a therapeuticeffect.

In some embodiments, the present invention includes one or moreconstituents which may or may not have pharmacological activity and thatare not typically susceptible to abuse in addition to a drug that issusceptible to abuse, described above. In certain embodiments, the oneor more constituents that are not typically susceptible to abuse canhave an abuse deterrent effect (as described in more detail below) whenadministered in combination with a drug which is susceptible to abuse.In one embodiment of a dosage form of the present invention whichincludes a drug that is susceptible to abuse, the one or more additionaldrugs which can induce an abuse deterrent effect can be included in thedosage form in a sub-therapeutic or sub-clinical amount.

As used herein, “sub-therapeutic” or “sub-clinical” refer to an amountof a referenced substance that if consumed or otherwise administered, isinsufficient to induce an abuse deterrent effect (e.g., nausea) in anaverage subject or is insufficient to meet or exceed the threshold dosenecessary for inducing an abuse deterrent effect.

Accordingly, when an embodiment of a dosage form of the presentinvention is administered in accordance with a health care providerprescribed dosage and/or manner, the one or more additional drugs whichcan induce an abuse deterrent effect will not be administered in anamount sufficient to induce an abuse deterrent effect. However, when acertain embodiment of the present invention is administered in a doseand/or manner that is different from a health care provider prescribeddose, (i.e., the drug is abused or the dosage form is tampered with) thecontent of a formulation which can cause an abuse deterrent effectaccording to the present invention will be sufficient to induce an abusedeterrent effect. Suitable examples of drugs which can be administeredin sub-therapeutic amounts in the present invention include niacin,atropine sulfate, homatropine methylbromide, sildenafil citrate,nifedipine, zinc sulfate, dioctyl sodium sulfosuccinate and capsaicin.

2. Lipids, Triglycerides, and Other Constituents Soluble in a Non-PolarSolvent

As described above, the present invention can include one or moretriglycerides, and in particular triglycerides that are soluble in anon-polar solvent. In other embodiments, the present invention caninclude one or more lipids, such as fatty acids or esters. In stillother embodiments, the present invention can include one or more otherconstituents that are soluble in a non-polar solvent. In someembodiments the present invention can include a combination of one ormore triglycerides, lipids, and other constituents that are soluble in anon-polar solvent.

Suitable triglycerides include triglycerides that are soluble innon-polar solvents, and upon dissolution in the non-polar solventtogether with one or more drugs, remain in the non-polar solvent andinterfere with the conversion of a precursor compound to a drug, and/orinterfere with crystallization and extraction of a drug (e.g. the samedrug as originally in the dosage form) or a drug converted from the oneor more precursor drugs (e.g methamphetamine), significantly reducing oreliminating the amount of drug that can be recovered from an illicitrecovery method.

In some embodiments, the triglyceride can prevent conversion of aprecursor compound (e.g. pseudoephedrine) to a drug susceptible to abusemethamphetamine) Without being bound by a particular theory, lithiumused in the one-pot method reacts preferentially with the triglyceride,necessitating additional lithium to convert the precursor compound tothe drug. The inclusion of triglyceride, therefore, results in eitherincomplete conversion of precursor compound, or a higher cost (i.e. thecost of additional lithium) to complete the illicit conversion.

Without wishing to be bound by a particular theory, when the drug is aprecursor compound (e.g. pseudoephedrine), the triglyceride caninterfere with the crystallization of the converted drug by forming acomplex with the converted drug in solution and can interfere with theextraction of the converted drug both by forming a complex with theconverted drug and by prolonging the process of filtering the converteddrug from the non-polar solvent. Unexpectedly, the inclusion of atriglyceride in compositions of the invention results in an undesirablylow yield of converted drug that can be isolated.

In some embodiments, a suitable triglyceride is solid at roomtemperature (about 20° C.).

Suitable triglycerides can include compounds such as triacetin, butyrin,tricaprylin, triheptanoin, trimyristin, trilinolein, triolein,tristearin (also referred to as stearin or glycerol stearate),tripalmitin, hydrogenated palm kernel oil, and hydrogenated palm oil.

Suitable lipids include, but are not limited to, fatty acids andmixtures of fatty acids (e.g. sesame oil).

Other constituents that are soluble in a non-polar solvent include, butare not limited to, monoglycerides (e.g. MYVACET® available from Kerry,Inc.), and tocopherols (e.g. vitamin E).

An example of suitable, commercially available triglyceride includesDYNASAN 118® Tri stearin from CREMER OLEO GmbH & Co. KG. An example ofanother suitable, commercially available triglyceride includes SOFTISAN154® hydrogenated palm kernel oil from CREMER OLEO GmbH & Co. KG.

In some embodiments the melting point of the triglyceride is at leastabout 40° C., 45° C., 50° C. 55° C., 60° C., 65° C., 60° C., 75° C., and80° C. In some embodiments the melting point of the triglyceride is inthe range of about 40° C. to about 50° C., about 45° C. to about 55° C.,about 50° C. to about 60° C., about 55° C.′ to about 65° C., about 60°C. to about 70° C., about 65° C. to about 75° C., and preferably about70° C. to about 80° C. In some embodiments it has been advantageouslyfound that by including a triglyceride with a higher melting point, aformulation of the invention can withstand heat generated during aprocess of manufacturing a dosage form, such as heat from a high speedpress during direct compression of a tablet formulation. Thus, standardmanufacturing techniques can be used with certain formulations of thepresent invention.

In some embodiments, a therapeutic composition includes a triglyceridein an amount of about 1 wt % to about 50 wt %; about 1 wt % to about 45wt %; about 1 wt % to about 40 wt %; about 1 wt % to about 35 wt %;about 1 wt % to about 30 wt %; about 1 wt % to about 25 wt %; about 1 wt% to about 20 wt %; about 5 wt % to about 15 wt %; about 6 wt % to about13.5 wt %; about 6.5 wt %; to about 13.5 wt %; about 7 wt % to about 13wt %; about 7.5 wt % to about 12.5 wt %; about 8 wt % to about 12 wt %;about 8.5 wt % to about 11.5 wt %; about 9 wt % to about 11 wt %; about9.5 wt % to about 10.5 wt %; or about 10 wt % to about 10.5 wt %.

In some embodiments, a therapeutic composition includes a triglyceridein an amount of at least about 1 wt %; at least about 3 wt %; at leastabout 5 wt %; at least about 8 wt %; at least about 10 wt %; at leastabout 12 wt %; at least about 15 wt %; at least about 18 wt %; or atleast about 20 wt %.

In some embodiments, a therapeutic composition includes a triglyceridein an amount of about 1 wt %; about 1.5 wt % about 2 wt %; about 2.5 wt%; about 3 wt %; about 3.5 wt %; about 4 wt %; about 4.5 wt %; about 5.0wt %; about 5.5 wt %; about 6 wt %; about 6.5 wt %; about 7 wt %; about7.5 wt %; about 8 wt %; about 8.5 wt %; about 9 wt %; about 9.5 wt %;about 9.6 wt %; about 9.7 wt %; about 9.8 wt %; about 9.9 wt %; about10.0 wt %; about 10.1 wt %; about 10.2 wt %; about 10.3 wt %; about 10.4wt %; about 10.5 wt %; about 10.6 wt %; about 10.7 wt %; about 10.8 wt%; about 10.9 wt %; about 11 wt %; 11.5 wt % about 12 wt %; about 12.5wt %; about 13 wt %; about 13.5 wt %; about 14 wt %; about 14.5 wt %;about 15.0 wt %; about 15.5 wt %; about 16 wt %; about 16.5 wt %; about17 wt %; about 17.5 wt %; about 18 wt %; about 18.5 wt %; about 19 wt %;about 19.5 wt %; or about 20 wt %.

In some embodiments, a therapeutic composition includes a triglyceridein an amount of about 20 mg to about 120 mg; about 20 mg to about 115mg; about 20 mg to about 110 mg; about 20 mg to about 105 mg; about 20mg to about 100 mg; about 20 mg to about 95 mg, about 20 mg to about 90mg; about 20 mg to about 85 mg; about 20 mg to about 80 mg; about 25 mgto about 75 mg; about 30 mg to about 70 mg; about 35 mg to about 65 mg;about 40 mg to about 60 mg; or about 45 mg to about 55 mg. In someembodiments, a therapeutic composition includes polyethylene oxide in anamount of about 20 mg; about 25 mg; about 30 mg; about 35 mg; about 40mg; about 45 mg; about 46 mg; about 47 mg; about 48 mg; about 49 mg;about 50 mg; about 51 mg; about 52 mg; about 53 mg; about 54 mg; about55 mg; about 60 mg; about 65 mg; about 70 mg; about 75 mg; about 80 mg;about 85 mg; about 90 mg; about 95 mg; about 100 mg; about 105 mg; about110 mg; about 115 mg; or about 120 mg.

3. Viscosity Increasing/Gel Forming Agents

As described above, the present invention can include one or moreviscosity increasing or gel forming agents (hereafter referred to as gelforming agents) which form a gel upon contact with a solvent.

Suitable gel forming agents include compounds that, upon contact with asolvent, absorb the solvent and swell, thereby forming a viscous orsemi-viscous substance that significantly reduces and/or minimizes theamount of free solvent which can contain an amount of solubilized drug,and which can be drawn into a syringe. The viscous or gelled materialcan also reduce the overall amount of drug extractable with the solventby entrapping the drug in a gel matrix. In some embodiments, suitablegel forming agents include pharmaceutically acceptable polymers,including hydrophilic polymers, such as hydrogels.

As noted in U.S. Publication No. 2006/0177380 and other references,suitable polymers exhibit a high degree of viscosity upon contact with asuitable solvent. The high viscosity can enhance the formation of highlyviscous gels when attempts are made by an abuser to crush and dissolvethe contents of a dosage form in an aqueous vehicle and inject itintravenously.

More specifically, in certain embodiments the polymeric material in thepresent invention forms a viscous or gelled material upon tampering. Insuch embodiments, when an abuser crushes and dissolves the dosage formin a solvent, a viscous or semi-viscous gel is formed. The increase inthe viscosity of the solution discourages the abuser from injecting thegel intravenously or intramuscularly by preventing the abuser fromtransferring sufficient amounts of the solution to a syringe to cause adesired “high” once injected. In some embodiments, the increase inviscosity of the solution discourages the use of legitimate, over thecounter, and/or prescription drugs that are included in embodiments ofthe present invention in the illicit manufacture of other drugs.Specifically. the gel restricts the solubilization of the drug prior tothe conversion of the drug to another drug, e.g., the illicit use ofpseudoephedrine in the manufacture of methamphetatnine or methcathinone,as described below.

In certain embodiments, suitable polymers include one or morepharmaceutically acceptable polymers selected from any pharmaceuticalpolymer that will undergo an increase in viscosity upon contact with asolvent, e.g., as described in U.S. Pat. No. 4,070,494, the entirecontent of which is hereby incorporated by reference. Suitable polymerscan include alginic acid, polyacrylic acid, karaya gum, tragacanth,polyethylene oxide, polyvinyl alcohol, hydroxypropylcellulose, andmethyl cellulose including sodium carboxy methyl cellulose, hydroxyethylmethyl cellulose hydroxypropyl methyl cellulose and carbomers. In someembodiments, a therapeutic composition includes a combination ofpolyethylene oxide, and hydroxypropylcellulose. Other embodimentsfurther include ethylcellulose.

Polyethylene Oxide

In some embodiments, the therapeutic composition includes polyethyleneoxide. In certain embodiments, the polyethylene oxide can have anaverage molecular weight ranging from at least about 300,000 to about5,000,000; about 600,000 to about 5,000,000; about 800,000 to about5,000,000; about 1,000,000 to about 5,000,000; about 3,000,000 to about5,000,000; about 3,000,000 to about 8,000,000; and preferably at leastabout 5,000,000. In one embodiment, the polyethylene oxide includes ahigh molecular weight polyethylene oxide.

In one embodiment, the average particle size of the polyethylene oxideranges from about 840 to about 2,000 microns. In another embodiment, thedensity of the polyethylene oxide can range from about 1.15 to about1.26 g/ml. In another embodiment, the viscosity can range from about8,800 to about 17,600 cps.

A suitable polyethylene oxide used in a directly compressibleformulation of the present invention may be a homopolymer havingrepeating oxyethylene groups, i.e., —(—O—CH₂—CH₂—)_(n)—, where n canrange from about 2,000 to about 180,000. In some embodiments, thepolyethylene oxide is a commercially available and pharmaceuticallyacceptable homopolymer having moisture content of no greater than about1% by weight. Examples of suitable, commercially available polyethyleneoxide polymers include Polyox®, WSRN-1105 and/or WSR-coagulant,available from Dow chemicals. In another embodiment, the polymer can bea copolymer, such as a block copolymer of PEO and PPO. In someembodiments, the polyethylene oxide powdered polymers can contribute toa consistent particle size in a directly compressible formulation andeliminate the problems of lack of content uniformity and possiblesegregation.

In some embodiments, a therapeutic composition includes polyethyleneoxide in an amount of about 1 wt % to about 10 wt %; about 1.5 wt %; toabout 9 wt %; about 1.5 wt %; to about 8.5 wt %; about 2 wt % to about 8wt %; about 2.5 wt % to about 7.5 wt %; about 3 wt % to about 7 wt %;about 3.5 wt % to about 6.5 wt %; about 4 wt % to about 6 wt %; about4.5 wt % to about 5.5 wt %; or about 5 wt % to about 5.5 wt %.

In some embodiments, a therapeutic composition includes polyethyleneoxide in an amount of about 1 wt %; about 1.5 wt % about 2 wt %; about2.5 wt %; about 3 wt %; about 3.5 wt %; about 4 wt %; about 4.5 wt %;about 4.6 wt %; about 4.7 wt %; about 4.8 wt %; about 4.9 wt %; about5.0 wt %; about 5.1 wt %; about 5.2 wt %; about 5.3 wt %; about 5.4 wt%; about 5.5 wt %; about 5.6 wt %; about 5.7 wt %; about 5.8 wt %; about5.9 wt %; about 6 wt %; about 6.5 wt %; about 7 wt %; about 7.5 wt %; 8wt %; about 8.5 wt %; about 9 wt %; about 9.5 wt %; or about 10 wt %.

In some embodiments, a therapeutic composition includes polyethyleneoxide in an amount of about 5 mg to about 55 mg; about 5 mg to about 50mg; about 5 mg to about 45 mg; about 10 mg to about 40 mg; about 15 mgto about 35 mg; or about 20 mg to about 30 mg. In some embodiments, atherapeutic composition includes polyethylene oxide in an amount ofabout 5 mg; about 10 mg; about 15 mg; about 30 mg; about 40 mg; about 45mg; about 50 mg; or about 55 mg.

Constituents Which Gels in Polar and Non-Polar Solvents

In some embodiments, the therapeutic composition includes a constituentwhich gels in an organic solvent. In some embodiments, the therapeuticcomposition includes a constituent which gels in a non-polar solvent. Insome embodiments, the therapeutic composition includes a constituentwhich gels in a polar solvent. In some embodiments, the therapeuticcomposition includes hydroxypropylcellulose. While hydroxyproylcellulosecan form a gel when in contact with water, it can also form a gel whenin contact with organic solvents, particularly certain dry organicsolvents, e.g., ethyl alcohol.

In some embodiments, suitable hydroxypropylcellulose has a molecularweight of about 600,000 to about 1,300,000; about 1,000,000 to about1,300,000; about 1,100,000 to about 1,200,000; or about 1,150,000.

As noted above, high viscosity can enhance the formation of highlyviscous gels when attempts are made by an abuser to crush and dissolvethe contents of a dosage form in an aqueous vehicle and inject itintravenously. However, in certain embodiments, it has been found thatin the context of abuse deterrence selection of a lower viscosityhydroxypropylcellulose is suitable.

Accordingly, in certain embodiments, suitable hydroxypropylcellulose hasa viscosity of about 1,500 mPa to about 6,500 mPa; about 2,000 mPa toabout 6,500 mPa; about 2,500 mPa to about 6,500 mPa; about 3,000 mPa toabout 6,500 mPa; about 3,500 to about 6,500 mPa; about 4,000 mPa toabout 6,500 mPa; about 4,500 mPa to about 6,000 mPa; about 5,000 mPa toabout 5,500 mPa; about 1,500 mPa to about 3,000 mPa; about 2,000 mPa toabout 2,500 mPa; about 1,500 mPa to about 3,500 mPa; about 1,500 mPa toabout 4,000 mPa; about 1,500 mPa to about 4,500 mPa; about 1,500 mPa toabout 5,000 mPa; about 1,500 mPa to about 5,500 mPa; or about 1,500 toabout 6,000 mPa. In some embodiments, suitable hydroxypropylcellulosehas a viscosity of about 1,500 mPa; about 1,750 mPa, about 2,000 mPa;about 2,250 mPa; about 2,500 mPa; about 2,750 mPa; about 3,000 mPa;about 3,500 mPa; about 4,000 mPa; about 4,500 mPa; about 5,000 mPa;about 5,500 mPa; about 6,000 mPa; or about 6,500 mPa.

In some embodiments, suitable hydroxypropylcellulose has a D⁵⁰ particlesize of about 400 μm to about 1,000 μm, about 800 μm to about 1,000 μm;about 850 μm to about 950 μm; about 900 μm to about 950 μm; about 900 μmto about 930 μm; about 910 μm to about 920 μm; about 400 μm to about 650μm; about 450 μm to about 600 μm; about 500 μm to about 550 μm; or about510 μm to about 530 μm. In some embodiments, suitablehydroxypropylcellulose has a D⁵⁰ particle size of about 400 μm; about425 μm; about 450 μm; about 475 μm; about 500 μm; about 501 μm; about502 μm; about 503 μm; about 504 μm; about 505 μm; about 506 μm; about507 μm; about 508 μm; about 509 μm; about 510 μm; about 511 μm; about512 μm; about 513 μm; about 514 μm; about 515 μm; about 516 μm; about517 μm; about 518 μm; about 519 μm; about 520 μm; about 521 μm; about522 μm; about 523 μm; about 524 μm; about 525 μm; about 526 μm; about527 μm; about 528 μm; about 529 μm; about 530 μm; about 531 μm; about532 μm; about 533 μm; about 534 μm; about 535 μm; about 536 μm; about537 μm; about 538 μm; about 539 μm; about 540 μm; about 550 μm; about575 μm; about 600 μm; about 625 μm; about 650 μm; about 675 μm; about700 μm; about 725 μm; about 750 μm; about 775 μm; about 800 μm; about825 μm; about 850 μm; about 875 μm; about 900 μm; about 925 μm; about950 μm; about 975 μm; or about 1000 μm.

In certain embodiments, suitable hydroxypropylcellulose has a tapdensity of about 0.493 g/cm³ to about 0.552 g/cm³; about 0.498 g/cm³ toabout 0.547 g/cm³; about 0.503 g/cm³ to about 0.542 g/cm³; about 0.508g/cm³ to about 0.537 g/cm³ ; about 0.493 g/cm³ to about 0.523 g/cm³;about 0.498 g/cm³ to about 0.518 g/cm³; about 0.503 g/cm³ to about 0.513g/cm³; or about 0.506 g/cm³ to about 0.51 g/cm³. In some embodiments,suitable hydroxypropylcellulose has a tap density of about 0.493 g/cm³;about 0.498 g/cm³; about 0.503 g/cm³; about 0.504 g/cm³; about 0.505g/cm³; about 0.506 g/cm³; about 0.507 g/cm³; about 0.508 g/cm³; about0.509 g/cm³; about 0.510 g/cm³; about 0.511 g/cm³; about 0.512 g/cm³;about 0.517 g/cm³; about 0.522 g/cm³; about 0.527 g/cm³; about 0.532g/cm³; about 0.537 g/cm³; about 0.542 g/cm³; about 0.547 g/cm³; about552 g/cm³.

An example of suitable, commercially available hydroxypropylcelluloseincludes Klucel® Hydroxypropylcellulose from Aqualon Hercules, Inc.

Hydroxypropylcellulose is known in industry (like polyethylene oxide) asa polymer that is used in drug product matrices for creating a sustainedrelease profile. In sustained release forms, the typical concentrationsrange from about 15% to about 35% hydroxypropylcellulose. In certainembodiments, the present invention can include about 20% to about 40%hydroxypropylcellulose without compromising immediate releasecharacteristics. Immediate release characteristics are understood toinclude the release of an active promptly after administration.

In some embodiments, a therapeutic composition includeshydroxypropylcellulose in an amount of about 5 wt % to about 35 wt %;about 10 wt % to about 20 wt %; about 15 wt % to about 25 wt %; about 18wt % to about 22 wt %; or about 19 wt % to about 21 wt %, or about 20%to about 40%. In some embodiments, a therapeutic composition includeshydroxypropylcellulose in an amount of about 5 wt %; about 6 wt %; about7 wt %; about 8 wt %; about 9 wt %; about 10 wt %; about 11 wt %; about12 wt %; about 13 wt %; about 14 wt %; about 15 wt %; about 16 wt %;about 17 wt %; about 18 wt %; about 19 wt %; about 20 wt %; about 21 wt%; about 22 wt %; about 23 wt %; about 24 wt %; about 25 wt %, about30%, about 33 wt %; 37 wt %; or about 40 wt %. In some embodiments, atherapeutic composition includes hydroxypropylcellulose in an amount ofat least about 20 wt %.

In some embodiments, a therapeutic composition includeshydroxyproylcellulose in an amount of about 75 mg to about 125 mg; about80 mg to about 120 mg; about 85 mg to about 115 mg; about 90 mg to about110 mg; or about 95 mg to about 105 mg. In some embodiments, atherapeutic composition includes hydroxypropylcellulose in an amount ofabout 75 mg; about 80 mg; about 85 mg; about 90 mg; about 95 mg; about100 mg; about 105 mg; about 110 mg; about 115 mg; about 120 mg; or about125 mg.

In some embodiments, a therapeutic composition includes ethylcellulose.In some embodiments, suitable ethylcellulose includes an ethoxyl contentof about 45% to about 47%. In some embodiments, suitable ethylcelluloseincludes an ethoxyl content of about 45%; about 46%; or about 47%.

An example of suitable commercially available ethylcellulose includesEthocel Medium 70 by Dow Chemical.

In some embodiments, a therapeutic composition includes ethylcellulosein an amount of about 15 wt % to about 25 wt %; about 18 wt % to about22 wt %; or about 19 wt % to about 21 wt %. In some embodiments, atherapeutic composition includes ethylcellulose in an amount of about 15wt %; about 16 wt %; about 17 wt %; about 18 wt %; about 19 wt %; about20 wt %; about 21 wt %; about 22 wt %; about 23 wt %; about 24 wt %; orabout 25 wt %. In some embodiments, a therapeutic composition includesethylcellulose in an amount of about 20.41 wt %.

In some embodiments, a therapeutic composition includes ethylcellulosein an amount of about 75 mg to about 400 mg; about 75 mg to about 375mg; about 75 mg to about 350 mg; about 75 mg to about 325 mg; about 75mg to about 300 mg; about 75 mg to about 275 mg; about 75 mg to about250 mg; about 75 mg to about 225 mg; about 75 mg to about 200 mg; about75 mg to about 175 mg; about 75 mg to about 150 mg; about 75 mg to about125 mg; about 80 mg to about 120 mg; about 85 mg to about 115 mg; about90 mg to about 110 mg; or about 95 mg to about 105 mg. lit) someembodiments, a therapeutic composition includes ethylcellulose in anamount of about 75 mg; about 80 mg; about 85 mg; about 90 mg; about 95mg; about 100 mg; about 105 mg; about 110 mg; about 115 mg; about 120mg; about 125 mg; about 150 mg; about 175 mg; about 200 mg; about 225mg; about 250 mg; about 275 mg; about 300 mg; about 325 mg; about 350mg; about 375 mg; or about 400 mg.

Following the teachings set forth herein, other suitable gel formingagents can include one or more of the following polymers: polyvinylalcohol, hydroxypropyl methyl cellulose, carbomers, ethyl cellulose,cellulose acetate, cellulose acetate propionate, cellulose acetatebutyrate, cellulose acetate phthalate and cellulose triacetate,cellulose ether, cellulose ester, cellulose ester ether, and cellulose,acrylic resins comprising copolymers synthesized from acrylic andmethacrylic acid esters, the acrylic polymer may be selected from thegroup consisting of acrylic acid and methacrylic acid copolymers, methylmethacrylate copolymers, ethoxyetlryl methacrylates, cyanoetlrylmethacrylate, poly(acrylic acid), poly(methaerylic acid), methacrylicacid alkylamide copolymer, poly(methyl methacrylate), polymethacrylate,poly(methyl methacrylate)copolymer, polyacrylamide, aminoalkylmethacrylate copolymer, poly(methacrylic acid anhydride), and glycidylmethacrylate copolymers.

Any of the above described polymers can be combined together or combinedwith other suitable polymers, and such combinations are within the scopeof the present invention.

In one embodiment, the present invention can prevent less than or equalto about 95%, 94%, 70%, 60%, 54%, 50%, 45%, 40%, 36%, 32%, 30%, 27%,20%, 10%, 9%, 6%, 5% or 2% of the total amount of a pharmaceuticalsusceptible to abuse in a dosage form from being recovered from asolvent. Alternatively, in some embodiments the present invention canprevent less than or equal to about 95%, 94%, 70%, 60%, 54%, 50%, 45%,40%, 36%, 32%, 30%, 27%, 20%, 10%, 9%, 6%, 5%, or 2% of the total amountof precursor compound from being chemically converted from precursorcompound to a drug susceptible to abuse. Alternatively, in someembodiments the present invention can prevent less than or equal toabout 95%, 94%, 70%, 60%, 54%, 50%, 45%, 40%, 36%, 32%, 30%, 27%, 20%,10%, 9%, 6%, 5% or 2% of the total amount of any drug which is convertedfrom being recovered.

The above described agents can be optimized in light of the teachingsset forth herein as necessary or desired in terms of viscosity,molecular weight, etc. The present invention can be used to manufactureimmediate release and controlled drug release formulations. Controlledrelease formulations can include delayed release, bi-modal and tri-modalrelease, extended and sustained release oral solid dosage preparations.In some embodiments, immediate release therapeutic compositions of thepresent invention include polymers associated with controlled releaseformulations. In some embodiments, immediate release therapeuticcompositions of the present invention include polymers associated withcontrolled release formulations in an amount of at least about 75 wt %;at least about 70 wt %; at least about 65 wt %; at least about 60 wt %;at least about 55 wt %; at least about 50 wt %; at least about 45 wt %;at least about 40 wt %; at least about 35 wt %; at least about 30 wt %;at least about 25 wt %; at least about 20 wt %; at least about 15 wt %;at least about 10 wt %; or at least about 5 wt %.

Ratios of Constituents

In some embodiments, a first gelling polymer is present in combinationwith one or more different constituents (e.g. a gel forming polymer or atriglyceride).

In some embodiments, a first gelling polymer is present in combinationwith one or more different gel forming polymers. In certain embodiments,the first gel forming polymer is hydroxy propylcellulose and a secondpolymer is an ethylene oxide such as polyethylene oxide. In certainembodiments, the first gel forming polymer is ethylcellulose and asecond polymer is an ethylene oxide such as polyethylene oxide. Incertain embodiments, the first gel forming polymer ishydroxypropylcellulose and a second polymer is ethylcellulose.

In one embodiment, the ratio between a first gel forming polymer andanother gel forming polymer on a weight basis is or is about one of thefollowing ratios: 10:1, 9:1, 7:1, 6:1, 5:1, 4:1, 3:1, 2:1, 1:1, 1:2,1:3, 1:4, 1:5, 1:6, 1:7, 1:8, 1:9, and 1:10. In some embodiments, twodifferent gel forming polymers can be used. As used herein, “different”can be understood to mean chemically different and/or physicallydistinct, such as differences in viscosity, particle size, shape,density, etc. In some embodiments, a composition includes three or moregel forming polymers, wherein the ratio between any two gel formingpolymers is in accord with the above ratios.

In one embodiment, the ratio between hydroxypropylcellulose and anothergel forming polymer on a weight basis is or is about one of thefollowing ratios: 10:1, 9:1, 7:1, 6:1, 5:1, 4:1, 3:1, 2:1, 1:1, 1:2,1:3, 1:4, 1:5, 1:6, 1:7, 1:8, 1:9, and 1:10. In one embodiment, theratio between ethylcellulose and another gel forming polymer on a weightbasis is or is about one of the following ratios: 10:1, 9:1, 7:1, 6:1,5:1, 4:1, 3:1, 2:1, 1:1, 1:2, 1:3, 1:4, 1:5, 1:6, 1:7, 1:8, 1:9, and1:10. In one embodiment, the ratio between polyethylene oxide andanother gel forming polymer on a weight basis is or is about one of thefollowing ratios: 10:1, 9:1, 7:1, 6:1, 5:1, 4:1, 3:1, 2:1, 1:1, 1:2,1:3, 1:4, 1:5, 1:6, 1:7, 1:8, 1:9, and 1:10.

In one embodiment, the ratio between hydroxypropylcellulose andpolyethylene oxide on a weight basis is or is about one of the followingratios: 10:1, 9:1, 7:1, 6:1, 5:1, 4:1, 3:1, 2:1, 1:1, 1:2, 1:3, 1:4,1:5, 1:6, 1:7, 1:8, 1:9, and 1:10. In one embodiment, the ratio betweenethylcellulose and polyethylene oxide on a weight basis is or is aboutone of the following ratios: 10:1, 9:1, 7:1, 6:1, 5:1, 4:1, 3:1, 2:1,1:1, 1:2, 1:3, 1:4, 1:5, 1:6, 1:7, 1:8, 1:9, and 1:10. In oneembodiment, the ratio between hydroxypropylcellulose and ethycelluloseon a weight basis is or is about one of the following ratios: 10:1, 9:1,7:1, 6:1, 5:1, 4:1, 3:1, 2:1, 1:1, 1:2, 1:3, 1:4, 1:5, 1:6, 1:7, 1:8,1:9, and 1:10.

In other embodiments, the ratio of hydroxypropylcellulose and anothergel forming polymer on a weight basis is between or is between about 5:1and 1:10 In other embodiments, the ratio of hydroxypropylcellulose andanother gel forming polymer on a weight basis is between or is betweenabout 4:1 and 1:10. In other embodiments, the ratio ofhydroxypropylcellulose and another gel forming polymer on a weight basisis between or is between about 6:1 and 1:10. In other embodiments, theratio of hydroxypropylcellulose and another gel forming polymer on aweight basis is between or is between about 7:1 and 1:10. In otherembodiments, the ratio of hydroxypropylcellulose and another gel formingpolymer on a weight basis is between or is between about 8:1 and 1:10.In other embodiments, the ratio of hydroxy propylcellulose and anothergel forming polymer on a weight basis is between or is between about 9:1and 1:10. In other embodiments, the ratio of hydroxypropylcellulose andanother gel forming polymer on a weight basis is between or is betweenabout 10:1 and 1:10.

In other embodiments, the ratio of polyethylene oxide and another gelforming polymer on a weight basis is between or is between about 5:1 and1:10. In other embodiments, the ratio of polyethylene oxide and anothergel forming polymer on a weight basis is between or is between about 4:1and 1:10. In other embodiments, the ratio of polyethylene oxide andanother gel forming polymer on a weight basis is between or is betweenabout 6:1 and 1:10. In other embodiments, the ratio of polyethyleneoxide and another gel forming polymer on a weight basis is between or isbetween about 7:1 and 1:10. In other embodiments, the ratio ofpolyethylene oxide and another gel forming polymer on a weight basis isbetween or is between about 8:1 and 1:10. In other embodiments, theratio of polyethylene oxide and another gel forming polymer on a weightbasis is between or is between about 9:1 and 1:10. In other embodiments,the ratio of polyethylene oxide and another gel forming polymer on aweight basis is between or is between about 10:1 and 1:10.

In other embodiments, the ratio of ethylcellulose and another gelforming polymer on a weight basis is between or is between about 5:1 and1:10. In other embodiments, the ratio of ethylcellulose and another gelforming polymer on a weight basis is between or is between about 4:1 and1:10. In other embodiments, the ratio of ethylcellulose and another gelforming polymer on a weight basis is between or is between about 6:1 and1:10. In other embodiments, the ratio of ethylcellulose and another gelforming polymer on a weight basis is between or is between about 7:1 and1:10. In other embodiments, the ratio of ethylcellulose and another gelforming polymer on a weight basis is between or is between about 8:1 and1:10. In other embodiments, the ratio of ethylcellulose and another gelforming polymer on a weight basis is between or is between about 9:1 and1:10. In other embodiments, the ratio of ethylcellulose and another gelforming polymer on a weight basis is between or is between about 10:1and 1:10.

In certain embodiments, a gel forming polymer which forms a gel in apolar solvent is present in combination with a gel forming polymer whichforms a gel in a non-polar solvent. In some embodiments, the ratiobetween a gel forming polymer which forms a gel in a polar solvent and agel forming polymer which forms a gel in a non-polar solvent on a weightbasis is or is about one of the following ratios: 10:1, 9:1, 7:1, 6:1,5:1, 4:1, 3:1, 2:1, 1:1, 1:2, 1:3, 1:4, 1:5, 1:6, 1:7, 1:8, 1:9, and1:10.

In other embodiments, the ratio of a gel forming polymer which forms agel in a polar solvent and a gel forming polymer which forms a gel in anon-polar solvent on a weight basis is between about 5:1 and 1:10. Inother embodiments, the ratio of a gel forming polymer which forms a gelin a polar solvent and a gel forming polymer which forms a gel in anon-polar solvent on a weight basis is between or is between about 4:1and 1:10. In other embodiments, the ratio of a gel forming polymer whichforms a gel in a polar solvent and a gel forming polymer which forms agel in a non-polar solvent on a weight basis is between or is betweenabout 6:1 and 1:10. In other embodiments, the ratio of a gel formingpolymer which forms a gel in a polar solvent and a gel forming polymerwhich forms a gel in a non-polar solvent on a weight basis is between oris between about 7:1 and 1:10. In other embodiments, the ratio of a gelforming polymer which forms a gel in a polar solvent and a gel formingpolymer which forms a gel in a non-polar solvent on a weight basis isbetween or is between about 8:1 and 1:10. In other embodiments, theratio of a gel forming polymer which forms a gel in a polar solvent anda gel forming polymer which forms a gel in a non-polar solvent on aweight basis is between or is between about 9:1 and 1:10. In otherembodiments, the ratio of a gel forming polymer which forms a gel in apolar solvent and a gel forming polymer which forms a gel in a non-polarsolvent on a weight basis is between or is between about 10:1 and 1:10.

In some embodiments, a first gelling polymer is present in combinationwith one or more triglycerides. In some embodiments, the ratio between afirst gelling polymer and a triglyceride on a weight basis is or isabout one of the following ratios: 10:1, 9:1, 7:1, 6:1, 5:1, 4:1, 3:1,2:1, 1:1, 1:2, 1:3, 1:4, 1:5, 1:6, 1:7, 1:8, 1:9, and 1:10.

In certain embodiments the first gelling polymer ishydroxypropylcellulose. In certain embodiments where the first gellingpolymer is hydroxypropylcellulose, the triglyceride is tristearin. Inone embodiment, the ratio between hydroxypropylcellulose and tristearinon a weight basis is or is about one of the following ratios; 10:1, 9:1,7:1, 6:1, 5:1, 4:1, 3:1, 2:1, 1:1, 1:2, 1:3, 1:4, 1:5, 1:6, 1:7, 1:8,1:9, and 1:10. In certain embodiments where the first gelling polymer ishydroxypropylcellulose, the triglyceride is hydrogenated palm oil. Inone embodiment, the ratio between hydroxypropylcellulose andhydrogenated palm oil on a weight basis is or is about one of thefollowing ratios: 10:1, 9:1, 7:1, 6:1, 5:1, 4:1, 3:1, 1:2, 1:3, 1:4,1:5, 1:6, 1:7, 1:8, 1;9, and 1:10.

In certain embodiments the first gelling polymer is polyethylene oxide.In certain embodiments where the first gelling polymer is polyethyleneoxide, the triglyceride is tristearin. In one embodiment, the ratiobetween polyethylene oxide and tristearin on a weight basis is or isabout one of the following ratios: 10:1, 9:1, 7:1, 6:1, 5:1, 4:1, 3:1,2:1, 1:1, 1:2, 1:3, 1:4, 1:5, 1:6, 1:7, 1:8, 1:9, and 1:10. In certainembodiments where the first gelling polymer is polyethylene oxide, thetriglyceride is hydrogenated palm oil. In one embodiment, the ratiobetween polyethylene oxide and hydrogenated palm oil on a weight basisis or is about one of the following ratios: 10:1, 91, 7:1, 6:1, 5:1,4:1, 3:1, 2:1, 1, 1.2, 1;3, 1:4, 1:5, 1:6, 1:7, 1:8, 1:9, and 1:10.

In other embodiments, the ratio of a first gelling polymer and atriglyceride on a weight basis is between or is between about 5:1 and1:10. In other embodiments, the ratio of a first gelling polymer and atriglyceride on a weight basis is between or is between about 4:1 and1:10. In other embodiments, the ratio of a first gelling polymer and atriglyceride on a weight basis is between or is between about 6:1 and1:10. In other embodiments, the ratio of a first gelling polymer and atriglyceride on a weight basis is between or is between about 7:1 and1:10. In other embodiments, the ratio of a first gelling polymer and atriglyceride on a weight basis is between or is between about 8:1 and1:10. In other embodiments, the ratio of a first gelling polymer and atriglyceride on a weight basis is between or is between about 9:1 and1:10. In other embodiments, the ratio of a first gelling polymer and atriglyceride on a weight basis is between or is between about 10:1 and1:10.

In certain embodiments the first gelling polymer ishydroxypropylcellulose. In certain embodiments where the first gellingpolymer is hydroxypropylcellulose, the triglyceride is tristearin. Insome embodiments, the ratio of hydroxypropylcellulose and tristearin ona weight basis is between or is between about 5:1 and 1:10. In otherembodiments, the ratio of the ratio of hydroxypropylcellulose andtristearin on a weight basis is between or is between about 4:1 and1:10. In other embodiments, the ratio of the ratio ofhydroxypropylcellulose and tristearin on a weight basis is between or isbetween about 6:1 and 1:10. In other embodiments, the ratio of the ratioof hydroxypropylcellulose and tristearin on a weight basis is between oris between about 7:1 and 1:10. In other embodiments, the ratio of theratio of hydroxypropylcellulose and tristearin on a weight basis isbetween or is between about 8:1 and 1:10. In other embodiments, theratio the ratio of hydroxypropylcellulose and tristearin on a weightbasis is between or is between about 9:1 and 1:10. In other embodiments,the ratio of the ratio of hydroxypropylcellulose and tristearin on aweight basis is between or is between about 10:1 and 1:10.

In certain other embodiments where the first gelling polymer ishydroxypropylcellulose, the triglyceride is hydrogenated palm oil. Insome embodiments, the ratio of hydroxypropylcellulose and hydrogenatedpalm oil on a weight basis is between or is between about 5:1 and 1:10.in other embodiments, the ratio of the ratio of hydroxypropylcelluloseand hydrogenated palm oil on a weight basis is between or is betweenabout 4:1 and 1:10. In other embodiments, the ratio of the ratio ofhydroxypropylcellulose and hydrogenated palm oil on a weight basis isbetween or is between about 6:1 and 1:10. In other embodiments, theratio of the ratio of hydroxypropylcellulose and hydrogenated palm oilon a weight basis is between or is between about 7:1 and 1:10. In otherembodiments, the ratio of the ratio of hydroxypropylcellulose andhydrogenated palm oil on a weight basis is between or is between about8:1 and 1:10. In other embodiments, the ratio the ratio ofhydroxypropylcellulose and hydrogenated palm oil on a weight basis isbetween or is between about 9:1 and 1:10. In other embodiments, theratio of the ratio of hydroxypropylcellulose and hydrogenated palm oilon a weight basis is between or is between about 10:1 and 1:10.

In certain embodiments the first gelling polymer is polyethylene oxide.In certain embodiments where the first gelling polymer is polyethyleneoxide, the triglyceride is tristearin. In some embodiments, the ratio ofpolyethylene oxide and tristearin on a weight basis is between or isbetween about 5:1 and 1:10. In other embodiments, the ratio of the ratioof polyethylene oxide and tristearin on a weight basis is between or isbetween about 4:1 and 1:10. In other embodiments, the ratio of the ratioof polyethylene oxide and tristearin on a weight basis is between or isbetween about 6:1 and 1:10. In other embodiments, the ratio of the ratioof polyethylene oxide and tristearin on a weight basis is between or isbetween about 7:1 and 1:10. In other embodiments, the ratio of the ratioof polyethylene oxide and tristearin on a weight basis is between or isbetween about 8:1 and 1:10. In other embodiments, the ratio the ratio ofpolyethylene oxide and tristearin on a weight basis is between or isbetween about 9:1 and 1:10. In other embodiments, the ratio of the ratioof polyethylene oxide and tristearin on a weight basis is between or isbetween about 10:1 and 1:10.

In certain other embodiments where the first gelling polymer ispolyethylene oxide, the triglyceride is hydrogenated palm oil. In someembodiments, the ratio of polyethylene oxide and hydrogenated palm oilon a weight basis is between or is between about 5:1 and 1:10. In otherembodiments, the ratio of the ratio of polyethylene oxide andhydrogenated palm oil on a weight basis is between or is between about4:1 and 1:10. In other embodiments, the ratio of the ratio ofpolyethylene oxide and hydrogenated palm oil on a weight basis isbetween or is between about 6:1 and 1:10. In other embodiments, theratio of the ratio of polyethylene oxide and hydrogenated palm oil on aweight basis is between or is between about 7:1 and 1:10. In otherembodiments, the ratio of the ratio of polyethylene oxide andhydrogenated palm oil on a weight basis is between or is between about8:1 and 1:10. In other embodiments, the ratio the ratio of polyethyleneoxide and hydrogenated palm oil on a weight basis is between or isbetween about 9:1 and 1:10. In other embodiments, the ratio of the ratioof polyethylene oxide and hydrogenated palm oil on a weight basis isbetween or is between about 10:1 and 1:10.

4. Additional Constituents

The present invention can also optionally include other ingredients toenhance dosage form manufacture from a pharmaceutical composition of thepresent invention and/or alter the release profile of a dosage formingincluding a pharmaceutical composition of the present invention,including fillers, disintegrants, glidants, and lubricants.

a. Fillers

Some embodiments of the present invention include one or morepharmaceutically acceptable fillers/diluents. In some embodiments, atherapeutic composition includes any suitable binder or filler. In someembodiments, a therapeutic composition includes microcrystal linecellulose. In some embodiments, suitable microcrystalline cellulose canhave an average particle size ranging from 20 to about 200 μm,preferably about 100 μm. In some embodiments, the density ranges from1.512-1.668 g/cm³. In certain embodiments, suitable microcrystallinecellulose should have molecular weight of about 36,000. Otheringredients can include sugars and/or polyols.

An example of suitable commercially available microcrystalline celluloseincludes Avicel PH102 by FMC Corporation.

In some embodiments, a therapeutic composition includes microcrystallinecellulose in an amount of about 20 wt % to about 35 wt %; about 22 wt %to about 32 wt %; about 24 wt % to about 30 wt %; or about 26 wt % toabout 28 wt %. In some embodiments, a therapeutic composition includesmicrocrystalline cellulose in an amount of about 20 wt %; about 21 wt %;about 22 wt %; about 23 wt %; about 24 wt %; about 25 wt %; about 26 wt%; about 27 wt %; about 28 wt %; about 29 wt %; about 30 wt %; about 31wt %; about 32 wt %; about 33 wt %; about 34 wt %; or about 35 wt %. Insome embodiments, a therapeutic composition includes about 26.94 wt %.

In certain embodiments, a therapeutic composition includesmicrocrystalline cellulose in an amount of about 100 mg to about 160 mg;about 105 mg to about 155 mg; about 110 mg to about 150 mg; about 115 mgto about 145 mg; about 120 mg to about 140 mg; about 125 mg to about 135mg; or about 120 mg to about 135 mg. In certain embodiments, atherapeutic composition includes microcrystalline cellulose in an amountof about 100 mg; about 105 mg; about 110 mg; about 115 mg; about 120 mg;about 125 mg; about 130 mg; about 135 mg; about 140 mg; about 145 mg;about 150 mg; or 155 mg. In some embodiments, a therapeutic compositionincludes about 132 mg microcrystalline cellulose.

In some embodiments of the invention, the fillers which can be presentat about 10 to 65 percent by weight on a dry weight basis, also functionas binders in that they not only impart cohesive properties to thematerial within the formulation, but can also increase the bulk weightof a directly compressible formulation (as described below) to achievean acceptable formulation weight for direct compression. In someembodiments, additional fillers need not provide the same level ofcohesive properties as the binders selected, but can be capable ofcontributing to formulation homogeneity and resist segregation from theformulation once blended. Further, preferred fillers do not have adetrimental effect on the flowability of the composition or dissolutionprofile of the formed tablets.

b. Disintegrants

In some embodiments, the present invention can include one or morepharmaceutically acceptable disintegrants. Such disintegrants are knownto a skilled artisan. In some embodiments, a therapeutic compositionincludes crospovidone (such as Polyplasdone® XL) having a particle sizeof about 400 microns and a density of about 1.22 g/ml. In someembodiments, disintegrants can include, but are not limited to, sodiumstarch glycolate (Explotab®) having a particle size of about 104 micronsand a density of about 0.756 g/ml, starch (e.g., Starch 21) having aparticle size of about 2 to about 32 microns and a density of about0.462 g/ml, and croscarmellose sodium (Ac-Di-Sol) having a particle sizeof about 37 to about 73.7 microns and a density of about 0.529 g/ml. Thedisintegrant selected should contribute to the compressibility,flowability and homogeneity of the formulation. Further the disintegrantcan minimize segregation and provide an immediate release profile to theformulation. An immediate release drug product is understood in the artto allow drugs to dissolve with no intention of delaying or prolongingdissolution or absorption of the drug upon administration, as opposed toproducts which are formulated to make the drug available over anextended period after administration. In some embodiments, thedisintegrant(s) are present in an amount from about 2 wt % to about 25wt %.

In some embodiments, a therapeutic composition includes crospovidone inan amount of about 15 wt % to about 25 wt %; about 18 wt % to about 22wt %; or about 19 wt % to about 21 wt %. In some embodiments, atherapeutic composition includes crospovidone in an amount of about 15wt %; about 16 wt %; about 17 wt %; about 18 wt %; about 19 wt %; about20 wt %; about 21 wt %; about 22 wt %; about 23 wt %; about 24 wt %; orabout 25 wt %. In some embodiments, a therapeutic composition includescrospovidone in an amount of about 20.41 wt %.

In some embodiments, a therapeutic composition includes crospovidone inan amount of about 75 mg to about 125 mg; about 80 mg to about 120 mg;about 85 mg to about 115 mg; about 90 mg to about 110 mg; or about 95 mgto about 105 mg in some embodiments, a therapeutic composition includescrospovidone in an amount of about 75 mg; about 80 mg; about 85 mg;about 90 mg; about 95 mg; about 100 mg; about 105 mg; about 110 mg;about 115 mg; about 120 mg; or about 125 mg.

c. Glidants

In one embodiment, the present invention can include one or morepharmaceutically acceptable glidants, including but not limited tocolloidal silicon dioxide. In one embodiment, colloidal silicon dioxide(Cab-O-Sil®) having a density of about 0.029 to about 0.040 g/ml can beused to improve the flow characteristics of the formulation. Suchglidants can be provided in an amount of from about 0.1 wt % to about 1wt %; about 0.2 wt % to about 0.8 wt %; or about 0.2 to about 6 wt %. Insome embodiments, a therapeutic composition includes a glidant in anamount of about 0.1 wt %; about 0.2 wt %; about 0.3 wt %; about 0.4 wt%; about 0.5 wt %; about 0.6 wt %; about 0.7 wt %; about 0.8 wt %; about0.9 wt %; or about 1 wt %. In some embodiments, a therapeuticcomposition includes a glidant in an amount of about 0.41 wt %. In someembodiments, a therapeutic composition includes a glidant in an amountof about 1 mg to about 10 mg; about 1 mg to about 5 mg; or about 1 mg toabout 3 mg. In some embodiments, a therapeutic composition includes aglidant in an amount of about 1 mg; about 2 mg; about 3 mg; about 4 mg;about 5 mg; about 6 mg; about 7 mg; about 8 mg; about 9 mg; or about 10mg.

It will be understood, based on this invention, however, that whilecolloidal silicon dioxide is one particular glidant, other glidantshaving similar properties which are known or to be developed could beused provided they are compatible with other excipients and the activeingredient in the formulation and which do not significantly affect theflowability, homogeneity and compressibility of the formulation.

d. Lubricants

In one embodiment, the present invention can include one or morepharmaceutically acceptable lubricants, including but not limited tomagnesium stearate. In some embodiments, magnesium stearate has aparticle size of about 450 to about 550 microns and a density of about1.00 to about 1.80 g/ml. In some embodiments of the present invention, atherapeutic composition includes magnesium stearate having a particlesize of from about 5 to about 50 microns and a density of from about 0.1to about 1.1 g/ml. In certain embodiments, magnesium stearate cancontribute to reducing friction between a die wall and a pharmaceuticalcomposition of the present invention during compression and can ease theejection of the tablets, thereby facilitating processing. In someembodiments, the lubricant resists adhesion to punches and dies and/oraid in the flow of the powder in a hopper and/or into a die. In someembodiments, suitable lubricants are stable and do not polymerize withinthe formulation once combined. Other lubricants which exhibit acceptableor comparable properties include stearic acid, hydrogenated oils, sodiumstearyl fumarate, polyethylene glycols, and Lubritab®.

In certain embodiments, a therapeutic composition includes lubricant inan amount of about 0.1 wt % to about 5 wt %; about 0.1 wt % to about 3wt %; about 0.1 wt % to about 1 wt %; or about 0.1 wt % to about 0.5 wt%. In some embodiments, a therapeutic composition includes lubricant inan amount of about 0.1 wt %; about 0.2 wt %; about 0.3 wt %; about 0.4wt %; about 0.5 wt %; about 0.6 wt %; about 0.7 wt %; about 0.8 wt %;about 0.9 wt %; or about 1 wt %. In some embodiments, a therapeuticcomposition includes lubricant in an amount of about 0.5 mg to about 5mg; about 0.5 mg to about 3 mg; or 0.5 mg to about 1.5 mg. In someembodiments, a therapeutic composition includes lubricant in an amountof about 0.5 mg; about 1 mg; about 1.5 mg; about 2 mg; about 2.5 mg;about 3 mg; about 4 mg; about 5 mg; about 6 mg; about 7 mg; about 8 mg;about 9 mg; or about 10 mg.

In certain embodiments, the most important criteria for selection of theexcipients are that the excipients should achieve good contentuniformity and release the active ingredient as desired. The excipients,by having excellent binding properties, and homogeneity, as well as goodcompressibility, cohesiveness and flowability in blended form, minimizesegregation of powders in the hopper during direct compression.

B. Methods of Making

In some embodiments, any of the constituents may or may not besequestered from the other constituents during the manufacturing or inthe final dosage form (e.g., tablet or capsule). In some embodiments,one or more of the constituents (e.g., gel forming polymers, includingpolyethylene oxide, hydroxypropylcellulose, and ethylcellulose,triglycerides, including tristearin and hydrogenated palm kernel oil,disintegrant, fillers and/or drug susceptible to abuse) may besequestered. In some embodiments, one or more of the constituents (e.g.,gel forming polymers, including polyethylene oxide,hydroxypropylcellulose, and ethylcellulose, triglycerides, includingtristearin and hydrogenated palm kernel oil, disintegrant, fillersand/or drug susceptible to abuse) is blended and/or admixed such thatall or a portion of the constituents are in contact with otherconstituents and/or are not sequestered.

A pharmaceutical composition of the present invention including one ormore drugs, one or more triglycerides, and optionally other ingredients,can be suitably modified and processed to form a dosage form of thepresent invention. In this manner, an abuse deterrent compositioncomprising triglycerides, gel forming agents, emetics, and any otheroptional ingredients can be layered onto, coated onto, applied to,admixed with, formed into a matrix with, and/or blended with a drug andoptionally other ingredients, thereby providing a therapeuticcomposition of the present invention.

Suitable formulations and dosage forms of the present invention includebut are not limited to powders, caplets, pills, suppositories, gels,soft gelatin capsules, capsules and compressed tablets manufactured froma pharmaceutical composition of the present invention. The dosage formscan be any shape, including regular or irregular shape depending uponthe needs of the artisan.

Compressed tablets including the pharmaceutical compositions of thepresent invention can be direct compression tablets or non-directcompression tablets. In some embodiments, a dosage form of the presentinvention can be made by wet granulation, and dry granulation (e.g.,slugging or roller compaction). The method of preparation and type ofexcipients are selected to give the tablet formulation desired physicalcharacteristics that allow for the rapid compression of the tablets.After compression, the tablets must have a number of additionalattributes such as appearance, hardness, disintegrating ability, and anacceptable dissolution profile.

Choice of fillers and other excipients typically depend on the chemicaland physical properties of the drug, behavior of the mixture duringprocessing, and the properties of the final tablets. Adjustment of suchparameters is understood to be within the general understanding of oneskilled in the relevant art. Suitable fillers and excipients aredescribed in more detail above.

The manufacture of a dosage fours of the present invention can involvedirect compression and wet and dry granulation methods, includingslugging and roller compaction. In some embodiments, it is preferred touse direct compression techniques because of the lower processing timeand cost advantages.

Accordingly, and as described further below, a directly compressiblepharmaceutical composition of the present invention can be designedfollowing the teachings set forth herein that can deter one or more ofa) parenteral abuse of a drug, b) inhalation abuse of a drug, c) oralabuse of a drug, and d) conversion of a drug using illicit processes.

Steps for making the compositions or dosage forms include the step ofproviding one or more drugs described above and a triglyceride having adesired melting point and solubility in non-polar solvent as describedabove and/or providing an amount of gel forming polymer having a desiredmolecular weight or viscosity as described above, a disintegrant, and/orother ingredients in the amounts as described above.

By controlling the melting point and/or solubility of the triglyceride,a therapeutic composition suitable for use to deter drug abuse can beformed. In some embodiments, in addition to the routes of abuse notedabove, a composition according to the present invention inhibits thecrystallization and extraction of a drug susceptible to abuse from adrug or precursor compound.

C. Abuse Deterrence

1. Interference with Crystallization and Extraction of a DrugSusceptible to Abuse

Compositions of some embodiments of the present invention may restrict,reduce or diminish the crystallization and extractability of a drugsusceptible to abuse that is converted by illicit means from a precursordrug, such as methamphetamine or methionine converted from a precursorpseudoephedrine, obtained from pseudoephedrine dosage forms. Withoutbeing bound by a particular mode of action, in sonic embodiments,therapeutic compositions of the present invention can interfere with thecrystallization of a drug susceptible to abuse by forming a complex insolution with the converted drug. The triglyceride present incompositions of some embodiments of the present invention is soluble innon-polar organic solvents. Examples of such solvents include, but arenot limited to, cyclohexane, nonane, octane, heptane, pentane, andmixtures thereof, including, but not limited to Coleman Fuel (alsoreferred to as naptha or white gas).

Conversion of certain precursor compounds, including pseudoephedrine, tomethamphetamine may be attempted by a number of methods, including theNazi Method, the Red Phosphorous Method, and the Shake and Bake Method.In some embodiments, therapeutic compositions of the present inventioninhibit extraction of a converted drug from solution, such as the“one-pot” solution of the Shake and Bake Method.

Tristearin

In one embodiment, a therapeutic composition includes pseudoephedrineHCl, polyethylene oxide, hydroxypropylcellulose, microcrystallinecellulose, tristearin, crospovidone, and magnesium stearate. Thetherapeutic composition may include pseudoephedrine HCl in an amount ofabout 6.1 wt %, hydroxypropylcellulose in an amount of about 20.4 wt %;microcrystalline cellulose in an amount of about 39.4 wt %, tristearinin an amount of about 10.2 wt % crospovidone in an amount of about 20.4wt %; and magnesium stearate in an amount of about 0.4 wt %. A 490 mgtablet of such formulation may include 30 mg pseudoephedrine HCl; 15 mgpolyethylene oxide; 100 mg hydroxypropylcellulose; 193 mgmicrocrystalline cellulose; 50 mg tristearin; 100 mg crospovidone; and 2mg magnesium stearate. In such embodiment, suitablehydroxypropylcellulose has a molecular weight of about 1,150,000 and aviscosity of about 1,500 to about 3,000. Such therapeutic compositionmay provide an immediate release product.

One embodiment of the present invention is as follows:

Formulation 1 Component mg per Tablet % (wt/wt) Pseudoephethine HCl 306.1 Polyox WSR polethylene 15 3.1 oxide Klucel HF 100 20.4hydroxypropylcellulose Avicel PH102 193 39.4 microcrystalline celluloseDynasan 118 tristearin 50 10.2 Polyplasdone XL 100 20.4 crospovidoneMagnesium Stearate 2 0.4 Total 490 100.0

The formulation demonstrates an immediate release product which caninhibit the extraction of methamphetamine or methcathinone from anon-polar solvent by forming a complex with the methamphetamine ormethcathinone in solution. Examples of such solvents include, but arenot limited to Coleman Fuel.

The Shake and Bake Method is generally known to be employed in smallscale (gram quantities) production of methamphetamine. Formulation 1 wastested for interference with extraction of converted methamphetamine.

100 pseudoephedrine tablets of Formulation 1 were ground with a coffeegrinder. The powdered pills were then mixed with ¾ cups (or about 180mL) of ammonium nitrate. The powder was transferred to a 1 L bottle andcombined with 450 mL COLEMAN® fuel, ½ bottle cap of crushed sodiumhydroxide (gram quantity was recorded), and 1 bottle cap of water (mLquantity was recorded). The bottle was closed and the mixture stirredwith a magnetic stir bar for 5 minutes before the pressure was released.½ caps of crushed sodium hydroxide (grain quantity was recorded) wereadded every 20 minutes while stiffing, until a total of 30 g of sodiumhydroxide was added over 2 hours. Next, the mixture was filtered throughfluted filter paper into a 1 L flask. Hydrogen chloride gas was bubbledthrough the filtrate for approximately 1 minute. The precipitate wascollected by decanting off the liquid or filtration for about 30minutes. The resulting precipitate was a sticky semi-solid and comprisedabout 50% methamphetamine HCl.

Upon analyzing the dried solid, it was found that overall reaction yieldof methamphetamine HCl recovered was 5.7%. The typical yield ofmethamphetamine HCl from a commercially available product, such asSUDAFED®, is greater than about 80%.

Hydrogenated Palm Kernel Oil

In one embodiment, a therapeutic composition includes pseudoephedrineHCl, polyethylene oxide, hydroxypropylcellulose, microcrystallinecellulose, hydrogenated palm kernel oil, crospovidone, and magnesiumstearate. The therapeutic composition may include psuedoephedrine HCl inan amount of about 6.1 wt %, hydroxypropylcellulose in an amount ofabout 20.4 wt %; microcrystalline cellulose in an amount of about 39.4wt %, hydrogenated palm kernel oil in an amount of about 10.2 wt %crospovidone in an amount of about 20.4 wt %; and magnesium stearate inan amount of about 0.4 wt %. A 490 mg tablet of such formulation mayinclude 30 mg pseudoephedrine HCl; 15 mg polyethylene oxide; 100 mghydroxypropylcellulose; 193 mg microcrystalline cellulose; 50 mghydrogenated palm kernel oil; 100 mg crospovidone; and 2 mg magnesiumstearate. In such embodiment, suitable hydroxypropylcellulose has amolecular weight of about 1,150,000 and a viscosity of about 1,500 toabout 3,000. Such therapeutic composition may provide an immediaterelease product.

One embodiment of the present invention is as follows:

Formulation 2 Component mg per Tablet % (wt/wt) Pseudoephedrine HCl 306.1 Polyox WSR polethylene 15 3.1 oxide Klucel HF 100 20.4hydroxypropylcellulose Avicel PH102 193 39.4 microcrystalline celluloseSoftisan 154 hydrogenated 50 10.2 palm kernel oil Polyplasdone XL 10020.4 crospovidone Magnesium Stearate 2 0.4 Total 490 100.00

The Shake and Bake Method is generally known to be employed in smallscale (gram quantities) production of methamphetamine. Formulation 2 wastested for interference with extraction of converted methamphetamine.

100 pseudoephedrine tablets of Formulation 2 were ground with a coffeegrinder. The powdered pills were then mixed with ¾ cups (or about 180mL) of ammonium nitrate. The powder was transferred to a 1 L bottle andcombined with 450 mL COLEMAN® fuel, ½ bottle cap of crushed sodiumhydroxide (gram quantity was recorded), and 1 bottle cap of water (mLquantity was recorded). The bottle was closed and the mixture stirredwith a magnetic stir bar for 5 minutes before the pressure was released.½ caps of crushed sodium hydroxide (gram quantity was recorded) wereadded every 20 minutes while stirring, until a total of 30 g of sodiumhydroxide was added over 2 hours. Next, the mixture was filtered throughfluted filter paper into a 1 L flask. Hydrogen chloride gas was bubbledthrough the filtrate for approximately 1 minute. The precipitate wascollected by decanting off the liquid or filtration for about 30minutes. The resulting precipitate was a sticky semi-solid and comprisedabout 50% methamphetamine HCl.

The typical yield from commercial product is greater than about 80%.Upon analyzing the dried solid, it was found that overall reaction yieldof methamphetamine HCl recovered was 5.7%.

As used herein, the term “about” is understood to mean ±10% of the valuereferenced. For example, “about 45%” is understood to literally mean40.5% to 49.5%.

A number of references have been cited, the entire disclosures of whichare incorporated herein by reference.

We claim:
 1. A therapeutic composition comprising: a pharmaceutically effective amount of pseudoephedrine or a salt thereof; a triglyceride; hydroxypropylcellulose, polyethylene oxide; and a disintegrant selected from the group consisting of crospovidone, sodium starch glycolate and croscarmellose sodium.
 2. The therapeutic composition of claim 1, wherein the composition is an immediate release formulation.
 3. The therapeutic composition of claim 1, wherein the hydroxypropylcellulose has a viscosity of about 1,500 mPa to about 3,000 mPa at a concentration of 1% in water.
 4. The therapeutic composition of claim 1, wherein the hydroxypropylcellulose has a molecular weight of about 1,150,000.
 5. The therapeutic composition of claim 1, wherein the polyethylene oxide is present in an amount of about 3 wt % to about 7 wt %.
 6. The therapeutic composition of claim 1, wherein the polyethylene oxide is prose in an amount of about 5 wt % to about 10 wt %.
 7. The therapeutic composition of claim 1, wherein the triglyceride has a melting point of about 50° C. to about 80° C.
 8. The therapeutic composition of claim 1, wherein the triglyceride is tristearin.
 9. The therapeutic composition of claim 1, wherein the disintegrant is crospovidone and is present in an amount of about 15 wt % to about 25 wt %.
 10. The therapeutic composition of claim 1, wherein the di sintegrant is crospovidone and is present in an amount of about 18 wt % to about 22 wt %.
 11. The therapeutic composition of claim 1, further comprising a glidant.
 12. The therapeutic composition of claim 11, wherein the glidant comprises colloidal silicon dioxide.
 13. The therapeutic composition of claim 1, further comprising a lubricant.
 14. The therapeutic composition of claim 13, wherein the lubricant comprises magnesium stearate.
 15. The therapeutic composition of claim 1, wherein the composition is a suppository, capsule, caplet, pill, gel, soft gelatin capsule, or compressed tablet form.
 16. The therapeutic composition of claim 1, wherein the composition is in unit dose form.
 17. A composition suitable for reducing the chemical conversion of a precursor compound included in the composition to a drug susceptible to abuse comprising: a precursor compound that can be used in a chemical synthesis of a drug that is susceptible to abuse; a triglyceride; hydroxypropylcellulose; polyethylene oxide; and a disintegrant selected from the group consisting of crospovidone, sodium starch glycolate and croscarmellose sodium.
 18. The composition of claim 17, wherein the precursor compound comprises pseudoephedrine.
 19. The composition of claim 17, wherein the composition is an immediate release composition.
 20. The therapeutic composition of composition of claim 16, wherein the unit dose form is a direct compressed unit dose form.
 21. A method of making a composition suitable for reducing the chemical conversion of precursor compound included in the composition to a drug susceptible to abuse comprising: providing ingredients comprising: a precursor compound that can be used in a chemical synthesis of a drug that is susceptible to abuse; a triglyceride, hydroxypropylcellulose; polyethylene oxide, and a disintegrant selected from the group consisting of crospovidone, sodium starch glycolate, and croscannellose sodium; and directly compressing the ingredients into a unit dose form. 